Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19.

Autor:	Munblit D; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.; Inflammation, Repair and Development Section, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.; Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Bobkova P; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Spiridonova E; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Shikhaleva A; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Gamirova A; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Blyuss O; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.; School of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, UK., Nekliudov N; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Bugaeva P; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Andreeva M; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., DunnGalvin A; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.; School of Applied Psychology, University College Cork, Cork City, Ireland., Comberiati P; Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy., Apfelbacher C; Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany., Genuneit J; Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany., Avdeev S; Clinic of Pulmonology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Kapustina V; Department of Internal Medicine №1, Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Guekht A; Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Fomin V; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Svistunov AA; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Timashev P; Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University, Moscow, Russia., Subbot VS; Department of Oncology, Radiotherapy and Plastic Surgery, University Clinical Hospital No 1, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Royuk VV; N.A. Semashko Department of Public Health and Healthcare, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Drake TM; Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK., Hanson SW; Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA., Merson L; Nuffield Department of Medicine, ISARIC Global Support Centre, University of Oxford, Oxford, UK., Carson G; Nuffield Department of Medicine, ISARIC Global Support Centre, University of Oxford, Oxford, UK., Horby P; Nuffield Department of Medicine, ISARIC Global Support Centre, University of Oxford, Oxford, UK., Sigfrid L; Nuffield Department of Medicine, ISARIC Global Support Centre, University of Oxford, Oxford, UK., Scott JT; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Semple MG; Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.; Department of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK., Warner JO; Inflammation, Repair and Development Section, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK., Vos T; Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA., Olliaro P; Nuffield Department of Medicine, ISARIC Global Support Centre, University of Oxford, Oxford, UK., Glybochko P; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Butnaru D; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2021 Sep; Vol. 51 (9), pp. 1107-1120. Date of Electronic Publication: 2021 Aug 12.
DOI:	10.1111/cea.13997
Abstrakt:	Background: The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Methods: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire. Results: 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions: Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms. (© 2021 John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF